Bio Essence Corp Annual Report: A Performance Summary

This guide breaks down Bio Essence Corp’s performance this year. Use this "cheat sheet" to decide if this company belongs in your portfolio.

1. What does this company do?

Bio Essence Corp has reinvented itself. After selling its factories in late 2023, the company now acts as a middleman. It provides consulting, supply chain management, and product development services for health and wellness brands. They no longer own production facilities. Instead, they manage the process, connecting raw material suppliers with third-party manufacturers to bring products to market.

2. Financial performance: A major turnaround

The new service-based model is gaining traction.

• Revenue Growth: Revenue jumped from $324,150 in 2024 to $1,895,000 in 2025. This 485% increase came from signing three major new clients in the supplement and skincare industries.
• Profitability: The company moved from a $1,520,000 loss in 2024 to an $895,000 profit in 2025. This happened because they no longer pay for expensive factory maintenance and labor.
• Efficiency: The company now keeps $0.75 of every dollar earned after direct costs. This is a massive improvement over the losses seen during their 2024 restructuring.

3. Major wins and challenges

• The Big Win: The pivot is working. By using third-party manufacturers, the company cut operating expenses by 60%. This allows more revenue to reach the bottom line.
• The Big Challenge: Despite the profit, the company is still fragile. They have a $9.54 million accumulated debt. Auditors have warned there is "substantial doubt" about the company’s ability to stay in business over the next year without more growth or new funding.
• Legal Headache: The company faces a $1.5 million lawsuit from Stason Industrial Corporation. This stems from a 2023 contract dispute and is nearly double the company’s current annual profit.

4. Financial health

With only four full-time employees, the company keeps costs very low. They do not plan to pay dividends, as they are using all available cash to pay down old debt and fund new contracts. The company also disclosed $450,000 in interest-free loans between the firm and a major shareholder. While these were paid back by year-end, it highlights a close relationship between the company’s finances and its executives' interests.

5. Key risks

• Going Concern: The company admits it needs constant, high-profit contracts to survive. If growth slows, they lack the cash to cover their $9.54 million debt.
• Operational Risk: Because they rely on outside manufacturers, they cannot control production quality or timelines. If a manufacturer fails to meet standards, Bio Essence suffers the consequences.
• Legal Risk: The $1.5 million lawsuit is a major threat. Losing this case could force the company into bankruptcy or require them to issue more shares, which would reduce your ownership percentage.

6. The Bottom Line

Bio Essence successfully pivoted to a growing service provider, showing a 485% revenue increase. However, it remains a high-risk investment. Before investing, weigh this turnaround against the auditor’s warnings, the legal threat, and the history of financial dealings with leadership. If you are looking for stability, the current debt load and legal exposure suggest this may be a speculative play rather than a core portfolio holding.